… aimed to explore the effect of S.boulardii or the oral non-absorbable antibiotic rifaximin on
top of guideline-recommended treatment for HF with reduced ejection fraction. In this proof-of-…

… and favourably affect cardiac function. … rifaximin or the probiotic yeast Saccharomyces
boulardii (ATCC 74012), on top of recommended treatment for HF, improves LV ejection fraction (…

… For example, nitrofurantoin and rifaximin could promote the growth of probiotics in intestines
… Patients with HF who were treated with S. boulardii for three months also showed significant …

… with reduced ejection fraction: Results from the randomized GutHeart trial We could not
demonstrate any significant effect of rifaximin or S Boulardii intervention on LVEF. For rifaximin …

… Simpson’s disk method, and ejection fraction was … Saccharomyces boulardii CNCM I-745
in eradicating SIBO in cirrhosis was 80%, which coincides with the effectiveness of rifaximin (76…

… The study found that specific probiotic strains led to an improvement in gut microbiota
composition, as well as an improvement in the left ventricular ejection fraction. Similarly, Moludi J. …

… Rifaximin or Saccharomyces boulardii in heart failure with reduced ejection fraction: results
… Three months’ treatment with Saccharomyces boulardii or rifaximin on top of SoC had no …

… improvement in ejection fraction in patients receiving the … In that study, NYHA Class II or
Class III heart failure patients (… antibiotic rifaximin or the probiotic Saccharomyces boulardii for a …

… function in well-treated HF with reduced ejection fraction [82]. All … in both rifaximin and
Saccharomyces boulardii groups. A possible explanation for the lack of clinical effect may be a low …

… The moderate to severe mitral regurgitation might explain why, in NYHA functional class
III to IV, there is the co-presence of a moderately reduced ejection fraction and a marginally …